Hypomethylating agents are standard in MDS treatment, with new drugs like Rytelo enhancing anemia management. Targeted therapies for IDH1/IDH2 mutations offer promising options, though challenges in ...

Study findings provide new tools to assess treatment preferences when using hypomethylating agents in myelodysplastic syndromes (MDS). The study aimed to develop the TPMQ for clinicians (mTPMQ), ...

Please provide your email address to receive an email when new articles are posted on . Most patients with newly diagnosed high-risk myelodysplastic syndrome do not receive guideline-recommended ...

Younger patients with relapsed MDS may benefit from DLI post-stem cell transplant, improving overall survival rates. DLI is associated with graft-versus-host disease, but its impact on prognosis is ...

Patients with MDS report more symptoms than physicians, indicating a communication gap in symptom assessment. Allogeneic hematopoietic stem cell transplantation is the only cure but is limited to ...

(WASHINGTON – August 6, 2025) – Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with hypomethylating agents (HMAs), according to results ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...

Most patients with high-risk myelodysplastic syndromes (MDS) do not receive guideline-recommended treatment with hypomethylating agents (HMAs), according to results published in Blood Neoplasia. The ...

Patients with myelodysplastic syndromes (MDS) suffer from a reduction in the number of different types of blood cells, including red blood cells leading to the development of anemia. Many patients ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...